<html><head></head><body><h1>Gallium Nitrate</h1><p class="drug-subtitle"><b>Class:</b> Bone Resorption Inhibitors<br/>
- Bone Resorption Inhibitors<br/>
<b>ATC Class:</b> V09HX01<br/>
<b>VA Class:</b> HS900<br/>
<b>Chemical Name:</b> Nitric acid gallium salt nonahydrate<br/>
<b>Molecular Formula:</b> GaN<sub>3</sub>O<sub>9</sub>•9H<sub>2</sub>O<br/>
<b>CAS Number:</b> 135886-70-3<br/>
<b>Brands:</b> Ganite</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>Concomitant Use with Nephrotoxic Drugs
<li>
<p>Risk of severe renal insufficiency in patients with cancer-related hypercalcemia when administered concomitantly with other potentially nephrotoxic drugs (e.g., aminoglycosides, amphotericin B).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Discontinue gallium if use of a potentially nephrotoxic drug is indicated; continue hydration for several days after administration of the nephrotoxic drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Closely monitor S<sub>cr</sub> and urine output during and after this period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If S<sub>cr</sub> exceeds 2.5 mg/dL, discontinue gallium therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Risk of severe renal insufficiency in patients with cancer-related hypercalcemia when administered concomitantly with other potentially nephrotoxic drugs (e.g., aminoglycosides, amphotericin B).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue gallium if use of a potentially nephrotoxic drug is indicated; continue hydration for several days after administration of the nephrotoxic drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Closely monitor S<sub>cr</sub> and urine output during and after this period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If S<sub>cr</sub> exceeds 2.5 mg/dL, discontinue gallium therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Bone resorption inhibitor.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Gallium Nitrate</h2><h3>Hypercalcemia</h3><p>Used in conjunction with adequate hydration for the management of symptomatic hypercalcemia associated with malignant neoplasms in patients whose hypercalcemia is not adequately managed with conventional methods of treatment (e.g., hydration alone);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; designated an orphan drug by FDA for this use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>More conservative measures than gallium therapy (e.g., hydration alone or combined with diuretics) generally are used for mild or asymptomatic hypercalcemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Bladder Cancer</h3><p>Has been used alone&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;14&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;15&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;17&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; and in combination with other antineoplastic agents&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;12&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;16&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; for the treatment of advanced or metastatic bladder carcinoma†; however, other agents are preferred.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Gallium Nitrate Dosage and Administration</h2><h3>General</h3><ul>Hypercalcemia
<li>
<p>Prior to initiating therapy, establish adequate hydration and urinary output in order to increase renal excretion of calcium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Maintain adequate hydration throughout therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Prior to initiating therapy, establish adequate hydration and urinary output in order to increase renal excretion of calcium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Maintain adequate hydration throughout therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Administer by slow IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dilute calculated daily dose, preferably in 1 L of 0.9% sodium chloride injection or 5% dextrose injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard unused portion of vial.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by slow IV infusion over 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>200 mg/m<sup>2</sup> daily for 5 consecutive days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If used for mild hypercalcemia and few associated symptoms, 100 mg/m<sup>2</sup> daily for 5 days may be used.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If optimum serum calcium concentrations are achieved in &lt;5 days, therapy may be discontinued early.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Safety and efficacy of repeated courses not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Contraindicated in patients with severe renal impairment (S<sub>cr</sub> &gt;2.5 mg/dL).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Caution if used in patients with mild to moderate renal impairment (S<sub>cr</sub> 2–2.5 mg/dL); manufacturer makes no specific recommendations regarding dosage in these patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Cautions.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Gallium Nitrate</h2><h3>Contraindications</h3><ul>
<li>
<p>Severe renal impairment (S<sub>cr</sub> &gt;2.5 mg/dL).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Severe renal impairment (S<sub>cr</sub> &gt;2.5 mg/dL).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Renal function abnormalities reported in clinical trials with gallium; hypercalcemia in cancer patients is commonly associated with impaired renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Establish adequate hydration and satisfactory urine output (e.g., 2 L daily) before initiating therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Maintain adequate hydration throughout treatment period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid overhydration in patients with compromised cardiovascular status.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitoring of S<sub>cr</sub> during gallium therapy is strongly recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue gallium if Scr &gt;2.5 mg/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Concomitant use of gallium with other nephrotoxic drugs may increase the risk of renal insufficiency in patients with cancer-related hypercalcemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Boxed Warning.)</p><p>Asymptomatic or mild to moderate hypocalcemia (6.5–8 mg/dL, corrected for albumin) may occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturer recommends daily monitoring of serum calcium concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If hypocalcemia occurs, discontinue gallium; short-term calcium replacement may be necessary.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Transient hypophosphatemia may occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Manufacturer recommends twice-weekly monitoring of serum phosphorus concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether gallium is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing or the drug. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established in children &lt;18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contraindicated in patients with S<sub>cr</sub> &gt;2.5 mg/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Safety and efficacy in these patients have not been examined systematically.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If used in patients with S<sub>cr</sub> of 2–2.5 mg/dL, monitor renal function frequently.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue if S<sub>cr</sub> increases beyond 2.5 mg/dL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Increased BUN and S<sub>cr</sub>, hypocalcemia, transient hypophosphatemia, decreased serum bicarbonate, decreased BP. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Gallium Nitrate</h2><h3>Nephrotoxic Drugs</h3><p>Potential increased risk of nephrotoxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue gallium if use of a potentially nephrotoxic drug is indicated; continue hydration for several days after administration of the nephrotoxic drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Closely monitor S<sub>cr</sub> and urine output during and after this period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If S<sub>cr</sub> &gt;2.5 mg/dL, discontinue gallium therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Cyclophosphamide</p><p>Dyspnea (occasionally associated with interstitial pneumonitis), mouth soreness, and asthenia reported in small number of multiple myeloma patients receiving low-dose gallium concomitantly with cyclophosphamide and prednisone&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diuretics (e.g., furosemide)</p><p>No apparent adverse interaction&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Gallium Nitrate Pharmacokinetics</h2><h3>Absorption</h3><p>Steady state reached in 24–48 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Not metabolized by liver or kidneys. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Substantially excreted by kidneys.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Average plasma clearance: 0.15 L/hour per kg. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>20–25°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Stable for 48 hours at 15–30°C or for 7 days at 2–8°C when diluted as recommended. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Dextrose 5% in water</p><p>Sodium chloride 0.9%</p><p>Compatible</p><p>Acyclovir sodium</p><p>Allopurinol sodium</p><p>Amifostine</p><p>Aminophylline</p><p>Ampicillin sodium-sulbactam sodium</p><p>Aztreonam</p><p>Cefazolin sodium</p><p>Ceftazidime</p><p>Ceftriaxone sodium</p><p>Cimetidine HCl</p><p>Ciprofloxacin</p><p>Cladribine</p><p>Co-trimoxazole</p><p>Cyclophosphamide</p><p>Dexamethasone sodium phosphate</p><p>Diphenhydramine HCl</p><p>Filgrastim</p><p>Fluconazole</p><p>Furosemide</p><p>Granisetron HCl</p><p>Heparin sodium</p><p>Hydrocortisone sodium succinate</p><p>Ifosfamide</p><p>Magnesium sulfate</p><p>Mannitol</p><p>Melphalan HCl</p><p>Meperidine HCl</p><p>Mesna</p><p>Methotrexate sodium</p><p>Metoclopramide HCl</p><p>Ondansetron HCl</p><p>Piperacillin sodium-tazobactam sodium</p><p>Potassium chloride</p><p>Ranitidine HCl</p><p>Sodium bicarbonate</p><p>Teniposide</p><p>Thiotepa</p><p>Ticarcillin disodium-clavulanate potassium</p><p>Vancomycin HCl</p><p>Vinorelbine tartrate</p><p>Incompatible</p><p>Cefepime HCl</p><p>Cisplatin</p><p>Cytarabine</p><p>Doxorubicin HCl</p><p>Etoposide</p><p>Fluorouracil</p><p>Haloperidol lactate</p><p>Hydromorphone HCl</p><p>Imipenem-cilastatin sodium</p><p>Lorazepam</p><p>Morphine sulfate</p><p>Prochlorperazine edisylate</p><h2>Actions</h2><ul>
<li>
<p>Exerts hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>No cytotoxic effects were seen on bone cells of animals treated with gallium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Exerts hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No cytotoxic effects were seen on bone cells of animals treated with gallium.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Risk of renal function abnormalities, hypocalcemia, and transient hypophosphatemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of laboratory monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing their clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Risk of renal function abnormalities, hypocalcemia, and transient hypophosphatemia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of laboratory monitoring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing their clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection</p><p>25 mg/mL (500 mg)</p><p>Ganite<sup></sup></p><p>Genta</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions June 1, 2007. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>1. Genta incorporated. Ganite<sup></sup> (gallium nitrate) injection prescribing information. Berkeley Heights, NJ; 2003 Sep.</p><p>2. Fujisawa Pharmaceutical Company: Personal communication.</p><p>3. Warrell RP Jr, Israel R, Frisone M et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized, double-blind comparison to calcitonin. <i>Ann Intern Med</i>. 1988; 108:669-74. http://www.ncbi.nlm.nih.gov/pubmed/3282463?dopt=AbstractPlus</p><p>4. Bilezikian JP. Management of acute hypercalcemia. <i>N Engl J Med</i>. 1992; 326:1196-203. http://www.ncbi.nlm.nih.gov/pubmed/1532633?dopt=AbstractPlus</p><p>5. Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414), to June 28, 1996. Rockville, MD; 1996 Jul.</p><p>6. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997:1300-22.</p><p>7. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. <i>J Clin Oncol</i>. 1997; 15:2449-55. http://www.ncbi.nlm.nih.gov/pubmed/9196161?dopt=AbstractPlus</p><p>8. Anon. Drugs of choice for cancer chemotherapy. <i>Med Lett Drugs Ther</i>. 2000; 42:83-92. http://www.ncbi.nlm.nih.gov/pubmed/10994034?dopt=AbstractPlus</p><p>9. Roth BJ. Chemotherapy for advanced bladder cancer. <i>Semin Oncol</i>. 1996; 23:633-44. http://www.ncbi.nlm.nih.gov/pubmed/8893874?dopt=AbstractPlus</p><p>10. Stadler WM, Kuzel T, Roth B et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. <i>J Clin Oncol</i>. 1997; 15:3394-8. http://www.ncbi.nlm.nih.gov/pubmed/9363871?dopt=AbstractPlus</p><p>11. Dreicer R, Propert KJ, Roth BJ et al. Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (E5892). <i>Cancer</i>. 1997; 79:110-4. http://www.ncbi.nlm.nih.gov/pubmed/8988734?dopt=AbstractPlus</p><p>12. Einhorn LH, Roth BJ, Ansari R et al. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. <i>J Clin Oncol</i>. 1994; 12:2271-6. http://www.ncbi.nlm.nih.gov/pubmed/7525884?dopt=AbstractPlus</p><p>13. Roth BJ. Ifosfamide in the treatment of bladder cancer. <i>Semin Oncol</i>. 1996; 23(Suppl 6):50-5. http://www.ncbi.nlm.nih.gov/pubmed/8677450?dopt=AbstractPlus</p><p>14. Crawford ED, Saiers JH, Baker LH et al. Gallium nitrate in advanced bladder cancer: Southwest Oncology Group study. <i>Urology</i>. 1991; 38:355-7. http://www.ncbi.nlm.nih.gov/pubmed/1755146?dopt=AbstractPlus</p><p>15. Seligman PA, Crawford ED. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. <i>J Natl Cancer Inst</i>. 1991; 83:1582-4. http://www.ncbi.nlm.nih.gov/pubmed/1960756?dopt=AbstractPlus</p><p>16. Schultz P, Bajorin D, Kelly WK et al. Combination gallium nitrate and 5-fluorouracil for platinum-resistant metastatic transitional cell carcinoma of the bladder. <i>Proc Annu Meet Am Soc Clin Oncol</i>. 1993; 34:203.</p><p>17. Seidman AD, Scher HI, Heinemann MH et al. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. <i>Cancer</i>. 1991; 68:2561-5. http://www.ncbi.nlm.nih.gov/pubmed/1933802?dopt=AbstractPlus</p><p>18. Reviewers’ comments (personal observations) on bladder cancer.</p><p>HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:770-2.</p><h2>More about gallium nitrate</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Drug Interactions</li>
<li>Drug class: miscellaneous bone resorption inhibitors</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hypercalcemia</li>
<li>Hypercalcemia of Malignancy</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>